{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T20:28:45Z","timestamp":1782160125235,"version":"3.54.5"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s11883-020-00844-w","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T17:10:28Z","timestamp":1591204228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Clinical Pharmacology of Statins: an Update"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7441","authenticated-orcid":false,"given":"Nicola","family":"Ferri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"issue":"9753","key":"844_CR1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Cholesterol Treatment Trialists","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet."},{"issue":"9841","key":"844_CR2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"C Cholesterol Treatment Trialists","year":"2012","unstructured":"Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet."},{"issue":"6","key":"844_CR3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/07853890.2018.1498118","volume":"50","author":"M Ruscica","year":"2018","unstructured":"Ruscica M, Ferri N, Macchi C, Corsini A, Sirtori CR. Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes? Ann Med. 2018;50(6):461\u201384.","journal-title":"Ann Med"},{"issue":"20","key":"844_CR4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301\u20137.","journal-title":"N Engl J Med"},{"issue":"20","key":"844_CR5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615\u201322.","journal-title":"JAMA."},{"issue":"21","key":"844_CR6","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"19","key":"844_CR7","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/CIRCULATIONAHA.117.032615","volume":"137","author":"I Taguchi","year":"2018","unstructured":"Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018;137(19):1997\u20132009.","journal-title":"Circulation."},{"issue":"22","key":"844_CR8","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1001\/jama.2013.281348","volume":"310","author":"FC Taylor","year":"2013","unstructured":"Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease. JAMA. 2013;310(22):2451\u20132.","journal-title":"JAMA"},{"key":"844_CR9","first-page":"CD004816","volume":"1","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. The Cochrane database of systematic reviews. 2013;1:CD004816.","journal-title":"The Cochrane database of systematic reviews"},{"issue":"11","key":"844_CR10","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","volume":"133","author":"I Ford","year":"2016","unstructured":"\u2022 Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of Scotland coronary prevention study. Circulation. 2016;133(11):1073\u201380 This study described for the first time a 20-year follow up results on safety and efficacy of pravastatin in primary prevention. The results reinforced the validity on using this therapeutic approach tp prevent CV diseases.","journal-title":"Circulation"},{"issue":"19","key":"844_CR11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease Study G","year":"1998","unstructured":"Long-Term Intervention with Pravastatin in Ischaemic Disease Study G. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"844_CR12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1071-9164(97)90022-1","volume":"3","author":"J Kjekshus","year":"1997","unstructured":"Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3(4):249\u201354.","journal-title":"J Card Fail"},{"issue":"1","key":"844_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"5","key":"844_CR14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","volume":"8","author":"P Amarenco","year":"2009","unstructured":"Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. The Lancet Neurology. 2009;8(5):453\u201363.","journal-title":"The Lancet Neurology"},{"issue":"17","key":"844_CR15","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"issue":"9753","key":"844_CR16","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","volume":"376","author":"J Armitage","year":"2010","unstructured":"Study of the Effectiveness of Additional Reductions in C, Homocysteine Collaborative G, Armitage J, Bowman L, Wallendszus K, Bulbulia R, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658\u201369.","journal-title":"Lancet"},{"key":"844_CR17","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","volume":"340","author":"J Hippisley-Cox","year":"2010","unstructured":"Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.","journal-title":"BMJ."},{"issue":"2","key":"844_CR18","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","volume":"39","author":"CB Newman","year":"2019","unstructured":"Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38\u201381.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9326","key":"844_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative G","year":"2002","unstructured":"Heart Protection Study Collaborative G. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet."},{"issue":"25","key":"844_CR20","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"A Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788\u201397.","journal-title":"Circulation."},{"issue":"11","key":"844_CR21","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","volume":"30","author":"G Chodick","year":"2008","unstructured":"Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther. 2008;30(11):2167\u201379.","journal-title":"Clin Ther"},{"issue":"3","key":"844_CR22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","volume":"6","author":"JD Cohen","year":"2012","unstructured":"Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. Journal of Clinical Lipidology. 2012;6(3):208\u201315.","journal-title":"Journal of Clinical Lipidology"},{"issue":"4","key":"844_CR23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","volume":"288","author":"CA Jackevicius","year":"2002","unstructured":"Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462\u20137.","journal-title":"JAMA"},{"issue":"38","key":"844_CR24","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","volume":"34","author":"R Chowdhury","year":"2013","unstructured":"Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940\u20138.","journal-title":"Eur Heart J"},{"issue":"11","key":"844_CR25","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","volume":"69","author":"MC Serban","year":"2017","unstructured":"Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"9716","key":"844_CR26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735\u201342.","journal-title":"Lancet"},{"issue":"24","key":"844_CR27","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556\u201364.","journal-title":"JAMA"},{"issue":"9841","key":"844_CR28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","volume":"380","author":"PM Ridker","year":"2012","unstructured":"Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565\u201371.","journal-title":"Lancet"},{"issue":"2","key":"844_CR29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2012.09.042","volume":"61","author":"DD Waters","year":"2013","unstructured":"Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013;61(2):148\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"844_CR30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","volume":"121","author":"S Mora","year":"2010","unstructured":"Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121(9):1069\u201377.","journal-title":"Circulation"},{"issue":"7","key":"844_CR31","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.2337\/dc13-0490","volume":"36","author":"MO Goodarzi","year":"2013","unstructured":"Goodarzi MO, Li X, Krauss RM, Rotter JI, Chen YD. Relationship of sex to diabetes risk in statin trials. Diabetes Care. 2013;36(7):e100\u20131.","journal-title":"Diabetes Care"},{"issue":"11","key":"844_CR32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-8587(14)70173-1","volume":"2","author":"SF Nielsen","year":"2014","unstructured":"Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. The Lancet Diabetes & endocrinology. 2014;2(11):894\u2013900.","journal-title":"The Lancet Diabetes & endocrinology"},{"issue":"4","key":"844_CR33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacc.2014.10.053","volume":"65","author":"P Kohli","year":"2015","unstructured":"Kohli P, Waters DD, Nemr R, Arsenault BJ, Messig M, DeMicco DA, et al. Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. J Am Coll Cardiol. 2015;65(4):402\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"844_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1567-5688(14)70002-9","volume":"16","author":"L Arnaboldi","year":"2015","unstructured":"Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl. 2015;16:1\u201327.","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"844_CR35","doi-asserted-by":"crossref","first-page":"e29849","DOI":"10.1371\/journal.pone.0029849","volume":"7","author":"JR Emberson","year":"2012","unstructured":"Cholesterol Treatment Trialists C, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PloS one. 2012;7(1):e29849.","journal-title":"PloS one"},{"issue":"4","key":"844_CR36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","volume":"6","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circulation Cardiovascular quality and outcomes. 2013;6(4):390\u20139.","journal-title":"Circulation Cardiovascular quality and outcomes"},{"issue":"1","key":"844_CR37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","volume":"97","author":"C Newman","year":"2006","unstructured":"Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97(1):61\u20137.","journal-title":"Am J Cardiol"},{"issue":"1","key":"844_CR38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.dld.2014.07.170","volume":"47","author":"D Pastori","year":"2015","unstructured":"Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2015;47(1):4\u201311.","journal-title":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver"},{"issue":"2","key":"844_CR39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","volume":"194","author":"A Sorokin","year":"2007","unstructured":"Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis. 2007;194(2):293\u20139.","journal-title":"Atherosclerosis."},{"issue":"3","key":"844_CR40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.beem.2013.11.006","volume":"28","author":"C Herrick","year":"2014","unstructured":"Herrick C, Litvin M, Goldberg AC. Lipid lowering in liver and chronic kidney disease. Best Pract Res Clin Endocrinol Metab. 2014;28(3):339\u201352.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"844_CR41","doi-asserted-by":"crossref","first-page":"e0151587","DOI":"10.1371\/journal.pone.0151587","volume":"11","author":"AT Clarke","year":"2016","unstructured":"Clarke AT, Johnson PC, Hall GC, Ford I, Mills PR. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. PLoS One. 2016;11(3):e0151587.","journal-title":"PLoS One"},{"issue":"2","key":"844_CR42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","volume":"56","author":"E Bjornsson","year":"2012","unstructured":"Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374\u201380.","journal-title":"J Hepatol"},{"issue":"1","key":"844_CR43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","volume":"2","author":"JA Salami","year":"2017","unstructured":"Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. JAMA Cardiol. 2017;2(1):56\u201365.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"844_CR44","doi-asserted-by":"crossref","first-page":"e007207","DOI":"10.1136\/bmjopen-2014-007207","volume":"5","author":"AG O'Keeffe","year":"2015","unstructured":"O'Keeffe AG, Petersen I, Nazareth I. Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England. BMJ Open. 2015;5(3):e007207.","journal-title":"BMJ Open"},{"issue":"10170","key":"844_CR45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","volume":"393","author":"Cholesterol Treatment Trialists C","year":"2019","unstructured":"\u2022 Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407\u201315 This metanalysis analyzed all the available data from RCT on safety and efficacy of statins in elderly. The results demonstrated that statin therapy produces significant reductions in major vascular events, irrespective of age. although there is less definitive direct evidence of benefit in the primary prevention setting among patients older than 75 years.","journal-title":"Lancet"},{"issue":"1","key":"844_CR46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/clc.22338","volume":"38","author":"KA Wilmot","year":"2015","unstructured":"Wilmot KA, Khan A, Krishnan S, Eapen DJ, Sperling L. Statins in the elderly: a patient-focused approach. Clin Cardiol. 2015;38(1):56\u201361.","journal-title":"Clin Cardiol"},{"issue":"3","key":"844_CR47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bcp.12687","volume":"80","author":"RB Iwere","year":"2015","unstructured":"Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;80(3):363\u201371.","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"844_CR48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","volume":"381","author":"IK Luirink","year":"2019","unstructured":"\u2022\u2022 Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-year follow-up of statins in children with familial hypercholesterolemia. N Engl J Med. 2019;381(16):1547\u201356 This study analyzed the efficacy of statins in children affected by familial hypercholesterolemia. A positive effect of statin treatment on on both surrogate and hard CV disease outcomes was observed, even if a modest percentage of patients with FH achieved their LDL-C target.","journal-title":"N Engl J Med"},{"issue":"32","key":"844_CR49","doi-asserted-by":"crossref","first-page":"24367","DOI":"10.1074\/jbc.M002184200","volume":"275","author":"JP Davies","year":"2000","unstructured":"Davies JP, Ioannou YA. Topological analysis of Niemann-Pick C1 protein reveals that the membrane orientation of the putative sterol-sensing domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and sterol regulatory element binding protein cleavage-activating protein. J Biol Chem. 2000;275(32):24367\u201374.","journal-title":"J Biol Chem"},{"issue":"5661","key":"844_CR50","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","volume":"303","author":"SW Altmann","year":"2004","unstructured":"Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303(5661):1201\u20134.","journal-title":"Science."},{"issue":"2","key":"844_CR51","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.gastro.2004.11.017","volume":"129","author":"F Lammert","year":"2005","unstructured":"Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology. 2005;129(2):718\u201334.","journal-title":"Gastroenterology."},{"issue":"1","key":"844_CR52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/14779072.1.1.11","volume":"1","author":"MH Davidson","year":"2003","unstructured":"Davidson MH. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther. 2003;1(1):11\u201321.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"844_CR53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3132\/dvdr.2006.020","volume":"3","author":"M Denke","year":"2006","unstructured":"Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res. 2006;3(2):93\u2013102.","journal-title":"Diab Vasc Dis Res"},{"issue":"10","key":"844_CR54","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","volume":"90","author":"C Gagne","year":"2002","unstructured":"Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1084\u201391.","journal-title":"Am J Cardiol"},{"issue":"9784","key":"844_CR55","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet."},{"issue":"25","key":"844_CR56","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"11","key":"844_CR57","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.molmed.2017.09.001","volume":"23","author":"SL Pinkosky","year":"2017","unstructured":"Pinkosky SL, Groot PHE, Lalwani ND, Steinberg GR. Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders. Trends Mol Med. 2017;23(11):1047\u201363.","journal-title":"Trends Mol Med"},{"key":"844_CR58","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.","journal-title":"Nat Commun"},{"issue":"11","key":"844_CR59","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"844_CR60","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA."},{"issue":"1","key":"844_CR61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","volume":"105","author":"SJ Nicholls","year":"2010","unstructured":"Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69\u201376.","journal-title":"Am J Cardiol"},{"issue":"7","key":"844_CR62","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"key":"844_CR63","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/211616s000lbl.pdf 2020."},{"issue":"11","key":"844_CR64","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","volume":"380","author":"BA Ference","year":"2019","unstructured":"Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019;380(11):1033\u201342.","journal-title":"N Engl J Med"},{"key":"844_CR65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","volume":"173","author":"N Ferri","year":"2016","unstructured":"Ferri N, Corsini A, Macchi C, Magni P, Ruscica M. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Translational Research: the journal of laboratory and clinical medicine. 2016;173:19\u201329.","journal-title":"Translational Research: the journal of laboratory and clinical medicine"},{"issue":"16","key":"844_CR66","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"issue":"22","key":"844_CR67","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"18","key":"844_CR68","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"7","key":"844_CR69","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamacardio.2019.0886","volume":"4","author":"SA Murphy","year":"2019","unstructured":"Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019;4(7):613\u20139.","journal-title":"JAMA Cardiol"},{"key":"844_CR70","doi-asserted-by":"crossref","first-page":"104413","DOI":"10.1016\/j.phrs.2019.104413","volume":"150","author":"C Macchi","year":"2019","unstructured":"Macchi C, Sirtori CR, Corsini A, Santos RD, Watts GF, Ruscica M. A new dawn for managing dyslipidemias: the era of rna-based therapies. Pharmacol Res. 2019;150:104413.","journal-title":"Pharmacol Res"},{"issue":"15","key":"844_CR71","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL Cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-020-00844-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-020-00844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T23:54:54Z","timestamp":1622678094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-020-00844-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s11883-020-00844-w","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"3 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Corsini reports personal fees from Sanofi, personal fees from Recordati, personal fees from Pfizer, personal fees from AstraZeneca, personal fees from Mylan, personal fees from DOC, personal fees from Mediolanum, personal fees from MSD, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"26"}}